Compare BridgeBio Pharma Inc (BBIO) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Weibo Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: BridgeBio Pharma Inc is far larger — about 8.6× Weibo Corp's market cap, and Weibo Corp pays a 7.65% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WB | |
|---|---|---|
Market Cap | $16.61B | $1.93B |
Sector | Health | Media |
52-Week High | $90.17 | $12.83 |
52-Week Low | $47.29 | $7.20 |
Enterprise Value | $18.16B | $1.20B |
Dividend Yield | — | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Weibo (WB) trades at $7.94, up 0.76% today, with neutral technical signals and strong fundamental metrics including a low P/E of 5.55 and robust 21.15% net income margin. Recent earnings show three consecutive quarterly misses but Q2 2026 results are pending. The company maintains solid cash flow generation with $519M operating cash flow in 2025, while analyst sentiment is mixed with 45% buy ratings.
WB presents value opportunity with discounted valuation metrics and strong profitability, though competitive pressures from Douyin and WeChat create headwinds. The stock's 8% dividend yield and cash-rich balance sheet provide downside protection, but investor sentiment remains cautious pending Q2 earnings results on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
